Advertisement

Psychopharmacology

, Volume 232, Issue 23, pp 4243–4252 | Cite as

Nicotine reinforcement in never-smokers

  • Angela N. Duke
  • Matthew W. Johnson
  • Chad J. Reissig
  • Roland R. Griffiths
Original Investigation

Abstract

Rationale

Global tobacco-related mortality dwarfs that of all other drugs. Nicotine is believed to be the primary agent responsible for tobacco use and addiction. However, nicotine is a relatively weak and inconsistent reinforcer in nonhumans and nicotine reinforcement has not been demonstrated in never-smokers.

Objectives

This study investigated the discriminative, subjective, and reinforcing effects of nicotine in never-smokers.

Methods

Eighteen never-smokers (<50 lifetime nicotine exposures) participated in a double-blind study. During a drug discrimination phase, volunteers ingested oral nicotine and placebo capsules (quasi-random order) at least 2 h apart and rated subjective effects repeatedly for 2 h after ingestion in daily sessions. Blocks of 10 sessions were continued until significant discrimination was achieved (p ≤ 0.05, binomial test; ≥8 of 10). Following discrimination, nicotine choice was tested by having volunteers choose which capsule set to ingest on each daily session. Successive blocks of 10 sessions were conducted until choice for nicotine or placebo met significance within each volunteer (≥8 of 10 sessions).

Results

All 18 volunteers significantly discriminated nicotine from placebo; the lowest dose discriminated ranged from 1.0 to 4.0 mg/70 kg. Nine volunteers significantly chose nicotine (choosers) and nine significantly chose placebo (nicotine avoiders). The choosers reported predominately positive nicotine subjective effects (e.g., alert/attentive, good effects, liking), while avoiders tended to report negative effects (e.g., dizzy, upset stomach, disliking). Both choosers and avoiders attributed their choice to the qualitative nature of drug effects.

Conclusions

These results provide the first evidence that nicotine can function as a reinforcer in some never-smokers.

Keywords

Nicotine Oral Never-smoker Drug discrimination Reinforcement Self-administration Subjective effects 

Notes

Acknowledgments

Conduct of this research was supported by NIH R01DA03890 and T32 DA07209. We thank Eric Richter, Crystal Barnhouser, Samantha Gebhart, Samuel King, Kevin Strouse, Jessica Vanderhoff, Elana Schwartz, and Julia Kane for serving as session monitors, Lisa Shade for technical assistance, Linda Felch for statistical assistance, and the pharmacy and medical staff. The study was conducted in compliance with United States laws. Dr. Reissig is an employee of the U.S. Food and Drug Administration (FDA); however, the views presented in this article do not necessarily reflect those of the FDA and no official support or endorsement of this article by the FDA is intended or should be inferred.

References

  1. Benowitz NL (1996) Pharmacology of nicotine: addiction and therapeutics. Annu Rev Pharmacol Toxicol 36:597–613CrossRefPubMedGoogle Scholar
  2. Benowitz NL, Jacob P, Denaro C, Jenkins R (1991) Stable isotope studies of nicotine kinetics and bioavailability. Clin Pharmacol Ther 49:270–277CrossRefPubMedGoogle Scholar
  3. College on Problems of Drug Dependence (1995) Human subject issues in drug abuse research. College on problems of drug dependence. Drug Alcohol Depend 37:167–175Google Scholar
  4. D’Orlando KJ, Fox BS (2004) Tolerability and pharmacokinetics of single and repeated doses of nicotine with the straw, a novel nicotine replacement product. Nicotine Tob Res 6:63–70CrossRefPubMedGoogle Scholar
  5. Dar R, Frenk H (2002) Nicotine self-administration in animals: a reevaluation. Addict Res Theory 10:545–579CrossRefGoogle Scholar
  6. Dar R, Frenk H (2004) Do smokers self-administer pure nicotine? A review of the evidence. Psychopharmacology 173:18–26CrossRefPubMedGoogle Scholar
  7. Dar R, Frenk H (2007) Reevaluating the nicotine delivery kinetics hypothesis. Psychopharmacology 192:1–7CrossRefPubMedGoogle Scholar
  8. Dar R, Kaplan R, Shaham L, Frenk H (2007) Euphoriant effects of nicotine in smokers: fact or artifact? Psychopharmacology 191:203–210CrossRefPubMedGoogle Scholar
  9. de Wit H, Phillips TJ (2012) Do initial responses to drugs predict future use or abuse? Neurosci Biobehav Rev 36:1565–1576PubMedCentralCrossRefPubMedGoogle Scholar
  10. de Wit H, Uhlenhuth EH, Johanson CE (1986) Individual differences in the reinforcing and subjective effects of amphetamine and diazepam. Drug Alcohol Depend 16:341–360CrossRefPubMedGoogle Scholar
  11. de Wit H, Uhlenhuth EH, Johanson CE (1987) The reinforcing properties of amphetamine in overweight subjects and subjects with depression. Clin Pharmacol Ther 42:127–136CrossRefPubMedGoogle Scholar
  12. Etter JF (2007) Addiction to the nicotine gum in never smokers. BMC Public Health 7:159–164PubMedCentralCrossRefPubMedGoogle Scholar
  13. Etter JF, Stapleton JA (2006) Nicotine replacement therapy for long-term smoking cessation: a meta-analysis. Tob Control 15:280–285PubMedCentralCrossRefPubMedGoogle Scholar
  14. Foltin RW, Fischman MW (1991) Methods for the assessment of abuse liability of psychomotor stimulants and anorectic agents in humans. Br J Addict 86:1633–1640CrossRefPubMedGoogle Scholar
  15. Gerlach KK, Rohay JM, Gitchell JG, Shiffman S (2008) Use of nicotine replacement therapy among never smokers in the 1999–2006 National Health and Nutrition Surveys. Drug Alcohol Depend 98:154–158CrossRefPubMedGoogle Scholar
  16. Goodwin AK, Hiranita T, Paule MG (2015) The reinforcing effects of nicotine in humans and nonhuman primates: a review of intravenous self-administration evidence and future directions for research. Nicotine Tob Res, in pressGoogle Scholar
  17. Griffiths RR, Brady JV, Bradford LD (1979) Predicting the abuse liability of drugs with animal drug self-administration procedures: psychomotor stimulants and hallucinogens, vol 2, Advances in behavioral pharmacology. Academic Press, Inc, New York, pp 163–208Google Scholar
  18. Haertzen CA, Kocher TR, Miyasato K (1983) Reinforcements from the first drug experience can predict later drug habits and/or addiction: results with coffee, cigarettes, alcohol, barbiturates, minor and major tranquilizers, stimulants, marijuana, hallucinogens, heroin, opiates and cocaine. Drug Alcohol Depend 11:147–165CrossRefPubMedGoogle Scholar
  19. Harvey DM, Yasar S, Heishman SJ, Panlilio LV, Henningfield JE, Goldberg SR (2004) Nicotine serves as a reinforce of intravenous drug-taking behavior in human cigarette smokers. Psychopharmacology 175:134–142CrossRefPubMedGoogle Scholar
  20. Heishman SJ, Henningfield JE (2000) Tolerance to repeated nicotine administration on performance, subjective, and physiological responses in nonsmokers. Psychopharmacology 152:321–333CrossRefPubMedGoogle Scholar
  21. Henningfield JE, Goldberg SR (1983) Nicotine as a reinforcer in human subjects and laboratory animals. Pharmacol Biochem Behav 19:989–992CrossRefPubMedGoogle Scholar
  22. Henningfield JE, Keenan RM (1993) Nicotine delivery kinetics and abuse liability. J Consult Clin Psychol 61:743–750CrossRefPubMedGoogle Scholar
  23. Houtsmuller EJ, Fant RV, Eissenberg TE, Henningfield JE, Stitzer ML (2002) Flavor improvement does not increase abuse liability of nicotine chewing gum. Pharmacol Biochem Behav 72:559–568CrossRefPubMedGoogle Scholar
  24. Hughes JR (1996) Who are these “nonsmokers”? Am J Public Health 86(5):745–746PubMedCentralCrossRefPubMedGoogle Scholar
  25. Hughes JR, Rose GL, Callas PW (2000) Do former smokers respond to nicotine differently from never smokers? a pilot study. Nicotine Tob Res 2:225–262Google Scholar
  26. Hughes JR, Shiffman S, Callas P, Zhang J (2003) A meta-analysis of the efficacy of the over-the-counter nicotine replacement. Tob Control 12:21–27PubMedCentralCrossRefPubMedGoogle Scholar
  27. Hukkanen J, Jacob P, Benowitz NL (2005) Metabolism and disposition kinetics of nicotine. Pharmacol Rev 57:79–115CrossRefPubMedGoogle Scholar
  28. Kalman D, Smith SS (2005) Does nicotine do what we think it does? a meta-analytic review of subjective effects of nicotine nasal spray and intravenous studies with smokers and nonsmokers. Nicotine Tob Res 7:317–333CrossRefPubMedGoogle Scholar
  29. King BA, Patel R, Nguyen KH, Dube SR (2014) Trends in awareness and use of electronic cigarettes among U.S. Adults, 2010–2013. Nicotine Tob Res PMID: 25239961Google Scholar
  30. Koffarnus MN, Winger G (2015) Individual differences in the reinforcing and punishing effects of nicotine in rhesus monkeys. Psychopharmacology 232:2393–2403CrossRefPubMedGoogle Scholar
  31. Le Foll B, Goldberg SR (2009) Effects of nicotine in experimental animals and humans: an update on addictive properties. Handb Exp Pharmacol 192:335–367CrossRefPubMedGoogle Scholar
  32. McClure JB, Swan GE (2006) Tailoring nicotine replacement therapy: rationale and potential approaches. CNS Drugs 20:281–291CrossRefPubMedGoogle Scholar
  33. McMillen RC, Gottlieb MA, Shaefer RMW, Winickoff JP, Klein JD (2014) Trends in electronic cigarette use among U.S. adults: use is increasing in both smokers and nonsmokers. Nicotine Tob ResGoogle Scholar
  34. Morel C, Fattore L, Pons S, Hay YA, Marti F, Lambolez B, De Biasi M, Lathrop M, Fratta W, Maskos U, Faure P (2014) Nicotine consumption is regulated by a human polymorphism in dopamine neurons. Mol Psychiatry 19(8):930–936CrossRefPubMedGoogle Scholar
  35. Neugenbauer NM, Cortright JJ, Sampedro GR, Vezina P (2014) Exposure to nicotine enhances its subsequent self-administration: contribution of nicotine-associated contextual stimuli. Behav Brain Res 260:155–161CrossRefGoogle Scholar
  36. Pastor V, Andres ME, Bernabeu RO (2013) The effect of previous exposure to nicotine on nicotine place preference. Psychopharmacology 226(3):551–560CrossRefPubMedGoogle Scholar
  37. Perkins KA (1999a) Nicotine discrimination in men and women. Pharmacol Biochem Behav 64(2):295–299CrossRefPubMedGoogle Scholar
  38. Perkins KA (1999b) Nicotine self-administration. Nicotine Tob Res 1:S133–S137CrossRefPubMedGoogle Scholar
  39. Perkins KA, Response to Dar and Frenk (2004) Do smokers self-administer pure nicotine? A review of the evidence. Psychopharmacology 175:256–258, author reply 259–261CrossRefPubMedGoogle Scholar
  40. Perkins KA, Sanders M, D’Amico D, Wilson A (1997) Nicotine discrimination and self-administration in humans as a function of smoking status. Psychopharmacology 131:361–37CrossRefPubMedGoogle Scholar
  41. Perkins KA, Gerlach D, Broge M, Fonte C, Wilson A (2001) Reinforcing effects of nicotine as a function of smoking status. Exp Clin Psychopharmacol 9:243–250CrossRefPubMedGoogle Scholar
  42. Robinson JH, Pritchard WS (1992) The role of nicotine in tobacco use. Psychopharmacology 108(4):397–407CrossRefPubMedGoogle Scholar
  43. Rose JE, Behm FM, Westman EC, Johnson M (2000) Dissociating nicotine and nonnicotine components of cigarette smoking. Pharmacol Biochem Behav 67:71–81CrossRefPubMedGoogle Scholar
  44. Schoenborn CA, Adams PF (2010) Health behaviors of adults: United States, 2005–2007. National Center for Health Statistics. Vital Health Stat 10(245)Google Scholar
  45. Schuck K, Otten R, Engels RC, Kleinjan M (2014) Initial responses to the first dose of nicotine in novel smokers: the role of exposure to environmental smoking and genetic predisposition. Psychol Health 29(6):698–716CrossRefPubMedGoogle Scholar
  46. Shahan TA, Bickel WK, Madden GJ, Badger GJ (1999) Comparing the reinforcing efficacy of nicotine containing and de-nicotinized cigarettes: a behavioral economic analysis. Psychopharmacology 147:210–216CrossRefPubMedGoogle Scholar
  47. Stolerman IP, Shoaib M (1991) The neurobiology of tobacco addiction. Trends Pharmacol Sci 12(12):467–473CrossRefPubMedGoogle Scholar
  48. Stone AA, Shiffman S (2002) Capturing momentary, self-report data: a proposal for reporting guidelines. Ann Behav Med 24(3):236–243CrossRefPubMedGoogle Scholar
  49. U.S. Department of Health and Human Services (2010) How tobacco smoke causes disease: the biology and behavioral basis for smoking-attributable disease: a report of the surgeon general, 4th edn, Nicotine addiction: past and present. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, AtlantaGoogle Scholar
  50. U.S. Department of Health and Human Services (2014) The health consequences of smoking—50 years of progress. A report of the surgeon general. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, Atlanta, Accessed 18 Dec 2014Google Scholar
  51. Vakkalanka JP, Hardison LS Jr, Hostege CP (2014) Epidemiological trends in electronic cigarette exposures reported to U.S. Poison Centers. Clin Toxicol 52(5):542–548CrossRefGoogle Scholar
  52. Wing VC, Shoaib M (2013) Effect of infusion rate on intravenous nicotine self-administration in rats. Behav Pharmacol 24(5–6):517–522CrossRefPubMedGoogle Scholar
  53. World Health Organization. WHO report on the global tobacco epidemic. 2013: enforcing bans on tobacco advertising, promotion, and sponsorship. http://www.who.int/tobacco/global_report/2013/en. Accessed on 18 Dec 2014

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  • Angela N. Duke
    • 1
  • Matthew W. Johnson
    • 1
  • Chad J. Reissig
    • 1
  • Roland R. Griffiths
    • 1
    • 2
  1. 1.Department of Psychiatry and Behavioral SciencesJohns Hopkins University School of MedicineBaltimoreUSA
  2. 2.Department of NeuroscienceJohns Hopkins University School of MedicineBaltimoreUSA

Personalised recommendations